Former BMS exec pleads guilty in Plavix case; Feds demand accused doc's financial records;

> A former senior exec at Bristol-Myers Squibb agreed to plead guilty and pay $1 million for misleading the government about the company's settlement of patent litigation over the Plavix blood thinner. Release

> Federal investigators subpoenaed financial records related to Scott S. Reuben, a Massachusetts doctor accused of faking data used in at least 21 anesthesiology studies, according to the hospital where he worked until recently. Report

> GlaxoSmithKline won European Commission authorization for Synflorix, a pediatric pneumococcal vaccine to protect against life-threatening diseases such as meningitis and bacteraemic pneumonia, as well as middle ear infections. Report

> Australian medicines company Dermatech is recalling batches of the skin ointment Dithrasal contaminated with a chemical linked to tumours in animals. Report

> Zacks Investment Research is keeping Pfizer stock at "Hold" because analysts there think the Wyeth acquisition won't lead to "long-term outperformance." Report

> Genzyme, the world's largest maker of drugs for rare genetic disorders, sued Impax Laboratories to block it from selling a generic version of the Renvela kidney medicine. Report

> University of Toronto biochemist Aled Edwards has been one of the leading champions of the open-source research movement in drug development. And he has some interesting numbers to back up his calls for a revolution in research. Report

> A national stem cell conference in the UK is providing plenty of fodder for anyone tracking the therapeutic potential of adult stem cells in healing bone and cartilage damage. Report

> AstraZeneca has filed a lawsuit to halt a generic form of its Pulmicort Respules asthma drug being sold by Apotex in the U.S. Report

> ReNeuron is touting new preclinical data backing the efficacy of its lead CTX stem cell line for peripheral arterial disease. Report

> Boston-based investor Richard Anders has set up a new angel fund to back life science start-ups. Report

> The Post-Bulletin of Rochester, MN sat down with biotech banker G. Steven Burrill, who bullishly amplified on his plans to invest $1 billion into the Pine Island biotechnology project. Report

> Shares of Renovo spiked this morning on news that the developer had received an unsolicited inquiry from an unnamed suitor. Report

And Finally... In the next few years, thousands of patients with implanted Sprint Fidelis defibrillator leads, made by Medtronic, may face surgery to remove and replace the potentially faulty cable. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.